Therapeutics for childhood neurofibromatosis type 1 and type 2

Current Treatment Options in Neurology

Volumn 13, Issue 6, 2011, Pages 529-543

  Ardern Holmes, Simone L ^a   North, Kathryn N ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICONVULSIVE AGENT; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; ERLOTINIB; EVEROLIMUS; HYDROXYUREA; IMATINIB; INTERFERON; LAPATINIB; MERLIN; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PSYCHOSTIMULANT AGENT; RAPAMYCIN; RAS PROTEIN; SIMVASTATIN; SOMATOSTATIN; SORAFENIB; VASCULOTROPIN INHIBITOR; VINCRISTINE;

ACOUSTIC NEURINOMA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUDITORY BRAIN STEM IMPLANT; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD DISEASE; COGNITIVE DEFECT; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; EARLY DIAGNOSIS; EPILEPSY; GENE; GENETIC SCREENING; GLIOBLASTOMA; HEADACHE; HEARING AID; HEART MURMUR; HUMAN; HYPERTENSION; LANGUAGE DISABILITY; LEARNING DISORDER; MENINGIOMA; MORBIDITY; MUTATIONAL ANALYSIS; NEUROFIBROMA; NEUROFIBROMATOSIS; NF1 GENE; NF2 GENE; NONHUMAN; OCCUPATIONAL THERAPY; OPTIC NERVE GLIOMA; PERIPHERAL NERVE TUMOR; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSIOTHERAPY; PRENATAL DIAGNOSIS; PSEUDARTHROSIS; RADIOSURGERY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCOLIOSIS; SPEECH THERAPY; SPINAL CORD TUMOR; TIBIAL PSEUDARTHROSIS; VASCULAR DISEASE;

EID: 81255160707     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-011-0142-9     Document Type: Article

References (65)

1. K Cichowski T Jacks 2001 NF1 tumor suppressor gene function: narrowing the GAP Cell 104 4 593 604 11239415 10.1016/S0092-8674(01)00245-8 1:CAS:528:DC%2BD3MXis1Kks7g%3D (Pubitemid 32201953)
2. AI McClatchey 2007 Neurofibromatosis Annu Rev Pathol 2 191 216 18039098 10.1146/annurev.pathol.2.010506.091940 1:CAS:528:DC%2BD2sXivV2isb0%3D (Pubitemid 46448064)
3. C Shilyansky KH Karlsgodt DM Cummings, et al. 2010 Neurofibromin regulates corticostriatal inhibitory networks during working memory performance Proc Natl Acad Sci USA 107 29 13141 6 20624961 10.1073/pnas.1004829107 1:CAS:528:DC%2BC3cXpsVCrtrs%3D
4. RE Ferner 2010 The neurofibromatoses Pract Neurol 10 2 82 93 20308235 10.1136/jnnp.2010.206532 This review comprehensively presents the clinical features and management approach for NF1 and NF2, including a number of clinical photographs
5. VC Williams J Lucas MA Babcock, et al. 2009 Neurofibromatosis type 1 revisited Pediatrics 123 1 124 33 19117870 10.1542/peds.2007-3204
6. RE Ferner SM Huson N Thomas, et al. 2007 Guidelines for the diagnosis and management of individuals with neurofibromatosis 1 J Med Genet 44 2 81 8 17105749 10.1136/jmg.2006.045906 1:CAS:528:DC%2BD2sXjt1Snsbs%3D
7. SL Hyman A Shores KN North 2005 The nature and frequency of cognitive deficits in children with neurofibromatosis type 1 Neurology 65 7 1037 44 16217056 10.1212/01.wnl.0000179303.72345.ce (Pubitemid 41429628)
8. VF Mautner L Kluwe SD Thakker, et al. 2002 Treatment of ADHD in neurofibromatosis type 1 Dev Med Child Neurol 44 3 164 70 12005317 10.1017/S0012162201001876 (Pubitemid 34232373)
9. JM Payne MD Moharir R Webster, et al. 2010 Brain structure and function in neurofibromatosis type 1: current concepts and future directions J Neurol Neurosurg Psychiatr 81 3 304 9 20185469 10.1136/jnnp.2009.179630
10. CV Dilts JC Carey JC Kircher, et al. 1996 Children and adolescents with neurofibromatosis 1: a behavioral phenotype J Dev Behav Pediatr 17 4 229 39 8856518 10.1097/00004703-199608000-00004 1:STN:280:DyaK2s%2FgvFCisQ%3D%3D
11. HL Thompson D Viskochil DA Stevenson, et al. 2010 Speech-language characteristics of children with neurofibromatosis type 1 Am J Med Genet A 152A 2 284 90 20101681 10.1002/ajmg.a.33235
12. W Li Y Cui SA Kushner, et al. 2005 The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1 Curr Biol 15 21 1961 7 16271875 10.1016/j.cub.2005.09. 043 1:CAS:528:DC%2BD2MXhtFyks7bP (Pubitemid 41566145)
13. R Listernick RE Ferner GT Liu, et al. 2007 Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations Ann Neurol 61 3 189 98 17387725 10.1002/ana.21107 1:CAS:528:DC%2BD2sXkvFykur8%3D (Pubitemid 46557343)
14. S Thiagalingam M Flaherty F Billson, et al. 2004 Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients Ophthalmology 111 3 568 77 15019338 10.1016/j.ophtha.2003.06.008 (Pubitemid 38293118)
15. L Chang MA El-Dairi TA Frempong, et al. 2010 Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas J AAPOS 14 6 511 7 21168074 10.1016/j.jaapos.2010.08.014
16. MJ Fisher L Balcer DH Gutmann, et al. 2010 Neurofibromatosis type 1 associated optic glioma visual outcomes following chemotherapy: an international multi-center retrospective analysis Neurooncol 12 6 ii19 20
17. T Rosser RJ Packer 2002 Intracranial neoplasms in children with neurofibromatosis 1 J Child Neurol 17 8 630 7 12403562 10.1177/ 088307380201700815 (Pubitemid 35203626)
18. BR Korf 1999 Plexiform neurofibromas Am J Med Genet 89 1 31 7 10469434 10.1002/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W 1:STN:280:DyaK1Mzpsl2nsQ%3D%3D (Pubitemid 30033174)
19. Nguyen R, Kluwe L, Fuensterer C, et al. Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. J Pediatr. 2011 May 27 (Epub ahead of print).
20. E Dombi J Solomon AJ Gillespie, et al. 2007 NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight Neurology 68 9 643 7 17215493 10.1212/01.wnl.0000250332.89420.e6 1:STN:280: DC%2BD2s7itlGnsA%3D%3D (Pubitemid 46667809)
21. FC Yang DA Ingram S Chen, et al. 2008 Nf1-dependent tumors require a microenvironment containing Nf1+/ - and c-kit-dependent bone marrow Cell 135 3 437 48 18984156 10.1016/j.cell.2008.08.041 1:CAS:528:DC%2BD1cXhtlyqtrzJ
22. DG Evans ME Baser J McGaughran, et al. 2002 Malignant peripheral nerve sheath tumours in neurofibromatosis 1 J Med Genet 39 5 311 4 12011145 10.1136/jmg.39.5.311 1:STN:280:DC%2BD383nt1Wquw%3D%3D (Pubitemid 34526349)
23. VF Mautner RE Friedrich A von Deimling, et al. 2003 Malignant peripheral nerve sheath tumours in neurofibromatosis type 1: MRI supports the diagnosis of malignant plexiform neurofibroma Neuroradiology 45 9 618 25 12898075 10.1007/s00234-003-0964-6 1:STN:280:DC%2BD3svksVKluw%3D%3D (Pubitemid 37236183)
24. M Moharir K London R Howman-Giles, et al. 2010 Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1 Eur J Nucl Med Mol Imag 37 7 1309 17 10.1007/s00259-010-1386-4
25. RE Friedrich M Hartmann VF Mautner 2007 Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children Anticancer Res 27 4A 1957 60 17649804 1:STN:280:DC%2BD2svivVGitA%3D%3D (Pubitemid 46954707)
26. AG Cairns KN North 2008 Cerebrovascular dysplasia in neurofibromatosis type 1 J Neurol Neurosurg Psychiatr 79 10 1165 70 18469031 10.1136/jnnp.2007. 136457 1:STN:280:DC%2BD1cngslSjsQ%3D%3D
27. R Vivarelli S Grosso F Calabrese, et al. 2003 Epilepsy in neurofibromatosis 1 J Child Neurol 18 338 42 12822818 10.1177/ 08830738030180050501 (Pubitemid 36798348)
28. M Ruggieri P Iannetti M Clementi, et al. 2009 Neurofibromatosis type 1 and infantile spasms Childs Nerv Syst 25 2 211 6 18802710 10.1007/s00381-008- 0706-5
29. VF Mautner L Kluwe RE Friedrich, et al. 2010 Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions J Med Genet 47 9 623 30 20543202 10.1136/jmg.2009.075937 1:CAS:528:DC%2BC3cXht1aru7bF
30. M Upadhyaya SM Huson M Davies, et al. 2007 An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation Am J Hum Genet 80 1 140 51 17160901 10.1086/510781 1:CAS:528:DC%2BD2sXms1CmtA%3D%3D (Pubitemid 46047657)
31. DG Evans A Wallace 2009 An update on age related mosaic and offspring risk in neurofibromatosis 2 (NF2) J Med Genet 46 11 792 19880713 10.1136/jmg.2009.070342 1:STN:280:DC%2BD1MjjtFWgsw%3D%3D
32. L Messiaen S Yao H Brems, et al. 2009 Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome JAMA 302 19 2111 8 19920235 10.1001/jama.2009.1663 1:CAS:528:DC%2BD1MXhsVequrzK
33. MJ Binning JK Liu JR Kestle, et al. 2007 Optic pathway gliomas: a review Neurosurg Focus 23 5 E2 18004964 10.3171/FOC-07/11/E2
34. RE Ferner DH Gutmann 2002 International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis Cancer Res 62 5 1573 7 11894862 1:CAS:528:DC%2BD38Xit1Kgsrs%3D (Pubitemid 34407825)
35. W Koptan Y El Miligui 2010 Surgical correction of severe dystrophic neurofibromatosis scoliosis: an experience of 32 cases Eur Spine J 19 9 1569 75 20506026 10.1007/s00586-010-1464-0
36. AA Baaj S Agazzi ZA Sayed, et al. 2009 Surgical management of moyamoya disease: a review Neurosurg Focus 26 4 E7 19335133 10.3171/2009.01.FOCUS08293
37. J Grill D Couanet C Cappelli, et al. 1999 Radiation-induced cerebral vasculopathy in children with neurofibromatosis and optic pathway glioma Ann Neurol 45 3 393 6 10072056 10.1002/1531-8249(199903)45:3<393::AID-ANA17>3. 0.CO;2-B 1:STN:280:DyaK1M7ntVaksA%3D%3D (Pubitemid 29120046)
38. TE Merchant LE Kun S Wu, et al. 2009 Phase II trial of conformal radiation therapy for pediatric low-grade glioma J Clin Oncol 27 22 3598 604 19581536 10.1200/JCO.2008.20.9494
39. LC Krab A de Goede-Bolder FK Aarsen, et al. 2008 Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial JAMA 300 3 287 94 18632543 10.1001/jama.300.3.287 1:CAS:528:DC%2BD1cXoslyqs7c%3D (Pubitemid 352008645)
40. A Kim A Gillespie E Dombi, et al. 2009 Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas Neurology 73 16 1273 9 19841379 10.1212/WNL.0b013e3181bd1326 1:STN:280: DC%2BD1Mjgt1yntg%3D%3D
41. RJ Packer DH Gutmann A Rubenstein, et al. 2002 Plexiform neurofibromas in NF1: toward biologic-based therapy Neurology 58 10 1461 70 12041525 1:CAS:528:DC%2BD38XkslSmsbc%3D (Pubitemid 34552949)
42. D Babovic-Vuksanovic K Ballman V Michels, et al. 2006 Phase II trial of pirfenidone in adults with neurofibromatosis type 1 Neurology 67 10 1860 2 17035676 10.1212/01.wnl.0000243231.12248.67 1:CAS:528:DC%2BD28Xht1SjsLzO (Pubitemid 44900770)
43. BC Widemann WL Salzer RJ Arceci, et al. 2006 Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas J Clin Oncol 24 3 507 16 16421428 10.1200/JCO.2005.03.8638 1:CAS:528:DC%2BD28XhsFSrsr8%3D (Pubitemid 46630471)
44. JL Kissil JO Blakeley RE Ferner, et al. 2010 What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers Am J Med Genet A 152A 2 269 83 20082461 10.1002/ajmg.a.33189 This article presents proceedings of the annual NF conference in 2009, including advances in understanding the pathophysiology of NF1 and NF2 and updates regarding clinical trials
45. SM Huson MT Acosta AJ Belzberg, et al. 2011 Back to the future: proceedings from the 2010 NF Conference Am J Med Genet A 155 2 307 21 10.1002/ajmg.a.33804 This article presents the most recent updates regarding scientific advances and translation to clinical trials for NF1 and NF2
46. NJ Ullrich M Zimmerman E Smith, et al. 2011 Association of rapidly progressive moyamoya syndrome with bevacizumab treatment for glioblastoma in a child with neurofibromatosis type 1 J Child Neurol 26 2 228 30 20823033 10.1177/0883073810379639
47. AR Asthagiri DM Parry JA Butman, et al. 2009 Neurofibromatosis type 2 Lancet 373 9679 1974 86 19476995 10.1016/S0140-6736(09)60259-2 1:CAS:528:DC%2BD1MXmvFajt70%3D
48. DG Evans 2009 Neurofibromatosis type 2 (NF2): a clinical and molecular review Orphanet J Rare Dis 4 16 19545378 10.1186/1750-1172-4-16 This review article provides a comprehensive overview of clinical, genetic, and management issues for patients with NF2
49. F Nunes M MacCollin 2003 Neurofibromatosis 2 in the pediatric population J Child Neurol 18 10 718 24 14649556 10.1177/08830738030180101301 (Pubitemid 37428072)
50. G Otsuka K Saito T Nagatani, et al. 2003 Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2 J Neurosurg 99 3 480 3 12959433 10.3171/jns.2003.99.3.0480 (Pubitemid 37040407)
51. DG Evans JM Birch RT Ramsden 1999 Paediatric presentation of type 2 neurofibromatosis Arch Dis Child 81 6 496 9 10569966 10.1136/adc.81.6.496 1:STN:280:DC%2BD3c%2FjvFymsA%3D%3D
52. M MacCollin VF Mautner 1998 The diagnosis and management of neurofibromatosis 2 in childhood Semin Pediatr Neurol 5 4 243 52 9874852 10.1016/S1071-9091(98)80003-X 1:STN:280:DyaK1M%2Fpt1Sisw%3D%3D (Pubitemid 29011300)
53. VF Mautner M Tatagiba R Guthoff, et al. 1993 Neurofibromatosis 2 in the pediatric age group Neurosurgery 33 1 92 6 8355853 10.1227/00006123-199307000- 00014 1:STN:280:DyaK3szmtFaitQ%3D%3D (Pubitemid 23204818)
54. DG Evans ME Baser B O'Reilly, et al. 2005 Management of the patient and family with neurofibromatosis 2: a consensus conference statement Br J Neurosurg 19 1 5 12 16147576 10.1080/02688690500081206 1:STN:280:DC%2BD2MvnslyhtQ%3D%3D (Pubitemid 40824366)
55. GJ Harris SR Plotkin M Maccollin, et al. 2008 Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II Neurosurgery 62 6 1314 9 18824998 10.1227/01.neu.0000333303.79931.83
56. DE Brackmann JN Fayad WH Slattery III, et al. 2001 Early proactive management of vestibular schwannomas in neurofibromatosis type 2 Neurosurgery 49 2 274 80 11504103 1:STN:280:DC%2BD3MvlslOktQ%3D%3D
57. DG Evans JM Birch RT Ramsden, et al. 2006 Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes J Med Genet 43 4 289 94 16155191 10.1136/jmg.2005.036319 1:STN:280:DC%2BD287pvVKitA%3D%3D
58. S Wentworth M Pinn JD Bourland, et al. 2009 Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors Int J Radiat Oncol Biol Phys 73 1 208 13 18687535 10.1016/j.ijrobp.2008.03.073
59. SR Plotkin AO Stemmer-Rachamimov FG Barker 2nd, et al. 2009 Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 N Engl J Med 361 4 358 67 19587327 10.1056/NEJMoa0902579 1:CAS:528:DC%2BD1MXovFCrsLY%3D
60. SR Plotkin C Halpin MJ McKenna, et al. 2010 Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients Otol Neurotol 31 7 1135 43 20736812 10.1097/MAO.0b013e3181eb328a
61. MC Chamberlain MJ Glantz CE Fadul 2007 Recurrent meningioma: salvage therapy with long-acting somatostatin analogue Neurology 69 10 969 73 17785665 10.1212/01.wnl.0000271382.62776.b7 1:CAS:528:DC%2BD2sXpsFaju78%3D (Pubitemid 47366049)
62. PY Wen WK Yung KR Lamborn, et al. 2009 Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08) Neuro Oncol 11 6 853 60 19293394 10.1215/15228517-2009-010 1:CAS:528:DC%2BC3cXotVOruw%3D%3D
63. BA Neff RM Wiet JM Lasak, et al. 2007 Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up Laryngoscope 117 6 1069 72 17545869 10.1097/MLG.0b013e31804b1ae7 (Pubitemid 46869847)
64. DG Evans M Kalamarides K Hunter-Schaedle, et al. 2009 Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2 Clin Cancer Res 15 16 5032 9 19671848 10.1158/1078-0432.CCR-08-3011 This consensus statement addresses challenges in clinical trials for NF2 and outlines current candidate medications
65. SR Plotkin C Halpin JO Blakeley, et al. 2009 Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma J Neurooncol 93 1 61 77 19430883 10.1007/s11060-009-9867-7 1:CAS:528:DC%2BD1MXls1yjsrY%3D